Sorafenib Tablets IP 200mg

Sorafenib Tablets IP 200mg Sorafenib is a targeted cancer therapy classified as a multikinase inhibitor. Each tablet contains 200 mg of Sorafenib tosylate, a molecule that inhibits multiple intracellular and cell surface kinases, including those involved in tumor cell signaling, angiogenesis (formation of new blood vessels that feed tumors), and apoptosis (programmed cell death). Indications: Hepatocellular carcinoma (HCC) – unresectable liver cancer. Renal cell carcinoma (RCC) – advanced kidney cancer. Differentiated thyroid carcinoma (DTC) – that is refractory to radioactive iodine treatment. Mechanism of Action: Sorafenib interferes with tumor cell proliferation and angiogenesis by inhibiting multiple kinases such as RAF kinase, VEGFR-2, VEGFR-3, PDGFR-β, KIT, FLT-3, and RET. This helps slow down or stop the spread of cancer. Dosage & Administration: The usual dose is 400 mg (two 200 mg tablets) twice daily, taken on an empty stomach or with a low-fat meal, or as directed by an oncologist. Side Effects May Include: Fatigue Diarrhea Hand-foot skin reaction Hypertension Rash Nausea Precautions: Regular monitoring of liver function, blood pressure, and skin reactions is essential. Not recommended in pregnancy. Dose adjustments may be required in patients with hepatic impairment.